Anaphylaxis in patients with hemophilia.
Anaphylactic reactions are rare emergencies observed in hemophilia patients. In hemophilia (B) (HB) patients they typically occur coincident with the development of an inhibitor. It is important to be aware of the possibility of such reactions, and the patient's family should be educated at the time of initial diagnosis and discussion. Because these reactions typically occur within the first 10 to 20 treatment courses, the first few infusions should be given in a hospital/clinic setting equipped to manage such emergencies. Obtaining the exact genotype may identify the HB patients at risk for this complication. When immune tolerance induction (ITI) is attempted in patients with HB inhibitors and anaphylaxis, the physician should be vigilant in detecting proteinuria.
Jadhav
M
M
Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Detroit 48201, USA.
Warrier
I
I
D000707:Anaphylaxis / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology; D005169:Factor VIII / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D002836:Hemophilia B / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007518:Isoantibodies / Q000009:adverse effects / Q000276:immunology; D014842:von Willebrand Diseases / Q000150:complications / Q000276:immunology
D007518:Isoantibodies; D005169:Factor VIII